318 related articles for article (PubMed ID: 23570380)
1. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
2. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
3. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
8. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
9. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Silver RT; Kiladjian JJ; Hasselbalch HC
Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
12. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
13. Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.
Kiladjian JJ
Am Soc Clin Oncol Educ Book; 2015; ():e389-96. PubMed ID: 25993201
[TBL] [Abstract][Full Text] [Related]
14. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
El Bitar S; Arcasoy MO
Clin Adv Hematol Oncol; 2024 Mar; 22(2):80-89. PubMed ID: 38446475
[TBL] [Abstract][Full Text] [Related]
16. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
18. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
19. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
[TBL] [Abstract][Full Text] [Related]
20. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
